Ten-year partnership will help Merck reduce operating costs, deliver value to patients and optimize the experience for healthcare professionals and patients
BARCELONA, Spain, Nov. 1, 2022 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced a ten-year strategic partnership agreement with Merck (NYSE: MRK), known as MSD outside the United States and Canada, which is based on the existing 12-year partnership between the companies. Under the terms of the agreement, Merck will take a Veeva-first approach to new industry-specific software and data, selecting Veeva products when appropriate to maximize the value of Veeva’s platform and integrated cloud-based products. . Veeva will provide Merck with a strategic pricing approach and Merck will be able to participate in Veeva’s product roadmap. The partnership helps accelerate Merck’s digital strategy and makes it more efficient for Merck to evaluate, purchase, operate and create value from Veeva’s products and services.
“The transformation of our digital, data and analytics capabilities is integral to enabling our global colleagues to fulfill our purpose of using the power of cutting-edge science to save and improve lives around the world,” said Robert M. Davis, CEO and President of Merck. Our strategic partnership with Veeva expands our ability to harness innovative technology and enhances our ability to deliver value to patients and all of our stakeholders, which is key to measuring success.”
“I am excited to see our partnership with Merck evolve to this strategic level,” said Veeva CEO Peter Gassner. “Our teams share a common passion for the industry and an understanding of strategic partnership. I look forward to seeing what we create together in the years to come.”
More information Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems Follow @veeva_eu on Twitter: twitter.com/veeva_eu
About Veeva Systems
Veeva is the world leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva serves more than 1,000 customers, from the world’s largest pharmaceutical companies to emerging biotech companies. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit the website veeva.com/eu.
Veeva Forward Looking Statements
This release contains forward-looking statements about Veeva’s products and services and the expected results or benefits from the use of our products and services, including some of our new solutions and applications that are still in development or not generally available. These statements are based on our current expectations. Actual results, availability and any future events related to these products and services could differ materially from those provided in this release and we have no obligation to update any such statements. There are numerous risks that may adversely affect our results, including the risks and uncertainties set forth in our filing on Form 10-Q for the period ended July 31, 2022, which you can find here (on pages 39-40). a summary of risks that may affect our business), and in our subsequent filings with the SEC, which you can access at sec.gov.
Contact:
Maria ScurryVeeva Systems781-366-7617maria.scurry@veeva.com
logo – link
View original content: enlace
